Evidence map›Paper›PMID 40236382›Full record

ArticleAnnals of thoracic medicine

Analysis of treatment efficacy, tolerability, and survival of patients receiving antifibrotic therapy for progressive nonidiopathic pulmonary fibrosis.

Nesrin Ocal, Aykut Cilli, Nesrin Mogulkoc, Funda Coskun, Ahmet Ursavas, Ismail Hanta, Berna Akinci Ozyurek, Kerem Ensarioglu, Alper Ezircan, Esra Yuksel and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of thoracic medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Nesrin OcalDepartment of Pulmonology, Gulhane Faculty of Medicine, Health Sciences University, Ankara, Turkey.
Aykut CilliDepartment of Pulmonology, Faculty of Medicine, Akdeniz University, Antalya, Turkey.
Nesrin MogulkocDepartment of Pulmonology, Faculty of Medicine, Ege University, İzmir, Turkey.
Funda CoskunDepartment of Pulmonology, Faculty of Medicine, Uludag University, Bursa, Turkey.
Ahmet UrsavasDepartment of Pulmonology, Faculty of Medicine, Uludag University, Bursa, Turkey.
Ismail HantaDepartment of Pulmonology, Faculty of Medicine, Cukurova University, Adana, Turkey.
Berna Akinci OzyurekDepartment of Pulmonology, Ataturk Sanatoryum Training and Research Hospital, Health Sciences University, Ankara, Turkey.
Kerem EnsariogluDepartment of Pulmonology, Ataturk Sanatoryum Training and Research Hospital, Health Sciences University, Ankara, Turkey.
Alper EzircanDepartment of Pulmonology, Faculty of Medicine, Ege University, İzmir, Turkey.
Esra YukselDepartment of Pulmonology, Gulhane Faculty of Medicine, Health Sciences University, Ankara, Turkey.
Beste ArikanDepartment of Pulmonology, Gulhane Faculty of Medicine, Health Sciences University, Ankara, Turkey.
Fatih UzerDepartment of Pulmonology, Faculty of Medicine, Akdeniz University, Antalya, Turkey.
Tugce Sahin OzdemirelDepartment of Pulmonology, Ataturk Sanatoryum Training and Research Hospital, Health Sciences University, Ankara, Turkey.
Salim MisirciDepartment of Rheumatology, Faculty of Medicine, Uludag University, Bursa, Turkey.
Pelin Pinar DenizDepartment of Pulmonology, Faculty of Medicine, Cukurova University, Adana, Turkey.
Ilknur BasyigitDepartment of Rheumatology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey.
Ozlem Ozdemir KumbasarDepartment of Rheumatology, Faculty of Medicine, Ankara University, Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere are still disagreements about diagnostic criteria and treatment of progressive pulmonary fibrosis (PPF). Real-life data and survival analyses have a guiding role in clarifying this issue.

methodsIn this multicenter retrospective cohort study, real-life data of adult patients diagnosed with PPF and treated with antifibrotics for at least 6 months were examined.

resultsOf the 222 patients, 161 were treated with Nintedanib (N) and 61 with Pirfenidone (P). The most common PPF subtype was connective tissue disease-related interstitial lung disease (CTD-ILD) (53.2%). The progression rate was significantly higher in patients with usual interstitial pneumonia (UIP) (

conclusionPPF subtypes have significant differences in terms of prognosis and survival. The effect of AF drugs on progression varies, especially among radiological patterns. An individualized approach is required in the diagnosis, follow-up, and treatment of patients with PPF.

Indexed as

Antifibroticidiopathic pulmonary fibrosisnintedanibpirfenidonepulmonary fibrosissurvival

Identifiers

PMID40236382
PMCPMC11996130

What Socratic holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.